Association between clinical pharmacist intervention intensity and clinical outcomes in diabetic kidney disease: a real-world analysis utilizing K-means clustering
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Diabetic kidney disease (DKD) is a key driver of end-stage renal disease, requiring intensive multidisciplinary care with clinical pharmacists as critical members. Though existing studies confirm pharmacist intervention efficacy, the relationship between intervention intensity and DKD patient outcomes remains poorly defined. Based on prior work, intervention intensity was quantified via two variable categories: (1) Clinical measures: therapeutic regimen optimization, Guideline-Directed Medical Therapy (GDMT) utilization and managing drug-drug interactions/adverse reactions; (2) Management metrics: medication education, physician acceptance of recommendation, medication rationality assessment and patient adherence evaluation. This study aimed to assess the association between clinical pharmacist intervention intensity and DKD patients’ key outcomes and prognosis via data-driven clustering. Methods Retrospective real-world cohort study at a Chinese Grade A tertiary hospital (May 2021–August 2025) assessed 148 inpatients, enrolling 97 patients were stratified via K-means clustering with uniform pharmacist intervention parameters; principal component analysis reduced dimensionality. Primary outcomes: eGFR. Secondary outcomes: UACR, HbA1c, readmission, dialysis initiation, MACE (heart failure, myocardial infarction, stroke, and cardiovascular death.). Results Of 97 inpatients, 58 had low-intensity and 39 had high-intensity clinical pharmacist intervention. Baseline characteristics were similar except for age. Changes from baseline to the 6-month follow-up, patients in the high-intensity group demonstrated significantly greater improvements in eGFR (median: 9.23 vs. −9.92 mL/min/1.73 m 2 , P < 0.05) and more pronounced reductions in UACR (median: −2038.21 vs . −901.92 mg/g, P < 0.05) and HbA1c (median: −1.17 vs. −0.24%, P < 0.05) compared with those in the low-intensity control group. In prognostic analysis, an eGFR decline (threshold: −10 mL/min/1.73 m 2 ) in the low-intensity group increased the incidence of MACE ( P = 0.020). Post hoc analyses identified medium-to-high adherence (OR = 4.058, 95% CI:1.167–14.111, P = 0.028) and ≥7 medication education sessions (OR = 6.250, 95% CI:1.996–17.574, P = 0.002) as independent predictors of eGFR improvement in DKD patients. Moreover, higher GDMT utilization/adherence correlated with greater eGFR improvement. Conclusion This study demonstrates that, compared with low-intensity intervention, high-intensity clinical pharmacist intervention is associated with better renal function and glycemic control, and may offer potential implications for delivering clinical value to high-risk patients. Limitations include the study’s limited follow-up duration and selection bias; future research will require larger samples and extended follow-up to confirm these findings.
Source: Frontiers in Pharmacology
Authors: Xinran Zhang(Conceptualization, Investigation, Project administration, Resources, Writing – original draft, Writing – review & editing), Menglin Li(Formal analysis, Methodology, Software, Writing – original draft), Xinyuan Song(Project administration, Supervision, Validation, Writing – review & editing), Yishan Bu(Funding acquisition, Project administration, Writing – review & editing)
Institutions: Tianjin First Center Hospital, Nankai University
Language: English
Subfield: Geriatrics and Gerontology
Field: Medicine
Domain: Health Sciences
Keywords: diabetic nephropathy, clinical pharmacist intervention, intervention intensity, guideline-directed medical therapy, medication adherence, estimated glomerular filtration rate decline, albumin-creatinine ratio, HbA1c, major adverse cardiovascular events, dialysis initiation, hospital readmission, medication education, drug-drug interactions, K-means clustering, multidisciplinary care, end-stage renal disease
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235394296
